Journal of the Formosan Medical Association
Volume 108, Issue 9 , Pages 746-750, September 2009

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis

  • Ming-Chao Tsai

      Affiliations

    • Divisions of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    • ,
  • Meng-Chih Lin

      Affiliations

    • Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    • ,
  • Chao-Hung Hung

      Affiliations

    • Divisions of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Chao-Hung Hung, Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Kaohsiung 833, Taiwan

Received 26 September 2007; received in revised form 11 February 2008; accepted 4 March 2008.

Article Outline

Pulmonary tuberculosis is a rare side effect of antiviral treatment for chronic hepatitis C. We present the case of 55-year-old woman with chronic hepatitis C, who developed pulmonary tuberculosis after receiving 8 weeks of peginterferon alfa-2a plus ribavirin therapy. Antituberculous treatment was started and antiviral agents were given continually at adjusted doses. Her symptoms of cough with blood-tinged sputum improved 1 month after antituberculous therapy. Treatment for hepatitis C and pulmonary tuberculosis were completed after 6 months. At 6 months after antiviral therapy, a sustained virological response was achieved and follow-up chest radiography showed a marked regressive change. This is believed to be the first case report of complete remission from hepatitis C and pulmonary tuberculosis treated concurrently with antiviral and antituberculous agents.

Key Words:  chronic hepatitis C , peginterferon alfa-2a , pulmonary tuberculosis , sustained virological response

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Zeuzem S , Welsch C , Herrmann E . Pharmacokinetics of peginterferons . Semin Liver Dis . 2003;23(Suppl 1):23–28
  2. Strader DB , Wright T , Thomas DL , et al.   Diagnosis, management, and treatment of hepatitis C . Hepatology . 2004;39:1147–1171
  3. Fried MW . Side effects of therapy of hepatitis C and their management . Hepatology . 2002;36:S237–S244
  4. Tahan V , Ozseker F , Guneylioglu D , et al.   Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature . Dig Dis Sci . 2003;48:169–173
  5. Kumar KS , Russo MW , Borczuk AC , et al.   Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C . Am J Gastroenterol . 2002;97:2432–2440
  6. Okanoue T , Sakamoto S , Itoh Y , et al.   Side effects of highdose interferon therapy for chronic hepatitis C . J Hepatol . 1996;25:283–291
  7. Murray JF . A century of tuberculosis . Am J Respir Crit Care Med . 2004;169:1181–1186
  8. El-Serag HB , Anand B , Richardson P , et al.   Association between hepatitis C infection and other infectious diseases: a case for targeted screening? . Am J Gastroenterol . 2003;98:167–174
  9. Hsueh PR , Liu YC , So J , et al.   Mycobacterium tuberculosis in Taiwan . J Infect . 2006;52:77–85
  10. Sabbatani S , Manfredi R , Marinacci G , et al.   Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis . Scand J Infect Dis . 2006;38:205–208
  11. Killingley B , Bhagani S , Slapak G , et al.   Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient . Haemophilia . 2006;12:545–547
  12. Roche Pharmaceuticals  . Pegasys®, Summary of Product Characteristics . Welwyn Garden City, UK: Roche Pharmaceuticals; 2005;
  13. Roche Pharmaceuticals  . Copegus®, Summary of Product Characteristics . Welwyn Garden City, UK: Roche Pharmaceuticals; 2003;
  14. Nahon P , Brugiere O , Marcellin P , et al.   Unexpected protective role of interferon-alpha against Mycobacterium tuberculosis during the course of hepatitis C antiviral therapy . Gastroenterol Clin Biol . 2004;28:609–610
  15. Yu ML , Dai CY , Lee LP , et al.   Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy . Antivir Ther . 2006;11:1015–1019
  16. Lee SD , Yu ML , Cheng PN , et al.   Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan . J Viral Hepat . 2005;12:283–291
  17. Kwon YS , Koh WJ , Suh GY , et al.   Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy . Chest . 2007;131:803–808

PII: S0929-6646(09)60400-9

doi:10.1016/S0929-6646(09)60400-9

Journal of the Formosan Medical Association
Volume 108, Issue 9 , Pages 746-750, September 2009

Article Tools